Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Akebia Therapeutics (AKBA) FCF Margin (2017 - 2025)

Akebia Therapeutics (AKBA) has disclosed FCF Margin for 9 consecutive years, with 53.9% as the latest value for Q4 2025.

  • On a quarterly basis, FCF Margin rose 6351.0% to 53.9% in Q4 2025 year-over-year; TTM through Dec 2025 was 28.66%, a 5407.0% increase, with the full-year FY2025 number at 28.66%, up 5407.0% from a year prior.
  • FCF Margin was 53.9% for Q4 2025 at Akebia Therapeutics, up from 47.69% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 69.39% in Q3 2022 to a low of 135.37% in Q1 2021.
  • A 5-year average of 28.57% and a median of 22.02% in 2022 define the central range for FCF Margin.
  • Peak YoY movement for FCF Margin: tumbled -16057bps in 2021, then surged 18481bps in 2022.
  • Akebia Therapeutics' FCF Margin stood at 108.9% in 2021, then surged by 70bps to 32.98% in 2022, then skyrocketed by 88bps to 4.11% in 2023, then tumbled by -134bps to 9.61% in 2024, then skyrocketed by 661bps to 53.9% in 2025.
  • Per Business Quant, the three most recent readings for AKBA's FCF Margin are 53.9% (Q4 2025), 47.69% (Q3 2025), and 35.57% (Q2 2025).